Kamada (NASDAQ: KMDA) — Company Overview, News & Financial Data
Kamada is a biopharmaceutical firm developing plasma-derived therapeutics for orphan indications and serious conditions.
Kamada
Kamada (TLV:KMDA), (NASDAQ:KMDA) is a biopharmaceutical firm focusing on the development, production, and marketing of specialty plasma-derived therapeutics for orphan indications and specific conditions. The company operates globally, channeling its efforts into plasma collection, leveraging its proprietary platform technology to produce a variety of high-purity proteins. Kamada aims to improve the quality of life for patients suffering from rare and serious diseases, including lung and immune disorders, by providing innovative and effective treatment options. Their project pipeline is robust, featuring both marketed products and compounds in various stages of clinical development, highlighting Kamada's commitment to advancing healthcare and meeting unmet medical needs worldwide.
Snapshot
Operations
Products and/or services of Kamada
- Glassia, the first liquid, ready-to-use, intravenous AAT replacement therapy.
- KedRAB, a post-exposure treatment against rabies infections.
- CYTOGAM, a cytomegalovirus immunoglobulin for organ transplant patients.
- KamRAB, a human rabies immunoglobulin for rabies post-exposure prophylaxis.
- KamRho(D) IG, an immunoglobulin for preventing Rh sensitization.
Kamada executive team
- Amir LondonChief Executive Officer
- Chaime OrlevChief Financial Officer
- Eran NirChief Operating Officer
- Jon R. KnightVice President of US Commercial Operations
- Boris GorelikVice President of Business Development & Strategic Programs
- David TsurCo-Founder & Independent Deputy Chairman of the Board
- Nir LivnehVP, General Counsel & Corporate Secretary
- Hanni NehemanVice President of Marketing & Sales
- Liron ReshefVice President of Human Resources
- Shavit BeladevVice President of Kamada Plasma
Dividend history
Dividends per share paid by Kamada, by financial year.
| Financial year | Interim | Final | Special | Total |
|---|---|---|---|---|
| FY2026(to date) | — | — | — | $0.4200 |
| FY2025 | — | — | — | $0.2000 |
| FY2013 | — | — | — | $0.0060 |
Key financials
Reported results for Kamada, in USD.
- Market cap
- 464.6M
- Revenue (TTM)
- 191.8M
- P/E ratio
- 21.2
- EPS (diluted, TTM)
- 0.4
- Dividend yield
- 2.1%
- Profit margin
- 11.6%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 180.5M | 26.2M | 20.2M | |
| 161M | 20.1M | 14.5M | |
| 142.5M | 10.1M | 8.3M | |
| 129.3M | 4.5M | -2.3M |